DAX22.987 +1,9%ESt505.404 +1,4%Top 10 Crypto11,88 +2,4%Dow41.488 +1,7%Nas17.754 +2,6%Bitcoin76.545 +0,9%Euro1,0877 -0,1%Öl71,02 +0,5%Gold2.990 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Tesla A1CX3T NVIDIA 918422 Steyr Motors A40TC4 RENK RENK73 HENSOLDT HAG000 Novo Nordisk A3EU6F Amazon 906866 Allianz 840400 Volkswagen (VW) vz. 766403 Palantir A2QA4J thyssenkrupp 750000 BASF BASF11 Deutsche Telekom 555750 Apple 865985
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Asiens Börsen in Grün -- Klarna plant IPO in den USA -- DHL, Porsche, TikTok im Fokus
Top News
NVIDIA-Aktie im Minus: Chinesischer Techkonzern Baidu mit neuen KI-Modelle NVIDIA-Aktie im Minus: Chinesischer Techkonzern Baidu mit neuen KI-Modelle
AmCham: Handelskrieg zwischen USA und EU könnte Billionen-Schaden verursachen AmCham: Handelskrieg zwischen USA und EU könnte Billionen-Schaden verursachen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Halozyme Therapeutics Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
56,98 EUR +0,70 EUR +1,24 %
FSE
62,24 USD +1,20 USD +1,97 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.7,05 Mrd. EUR

KGV13,93Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0DLHS

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS40637H1095

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolHALO

Halozyme Therapeutics Aktien News

DatumMeistgelesen
ZacksIs Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
ZacksWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
PR NewswireHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
BenzingaDecoding 12 Analyst Evaluations For Halozyme Therapeutics
PR NewswireHalozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
ZacksHalozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?
BenzingaHalozyme Therapeutics +13% On Thursday: What's Going On?
ZacksHalozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?
PR NewswireHalozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
PR NewswireHalozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
PR NewswireHalozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BenzingaA Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts
ZacksWhy Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
PR NewswireHalozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
PR NewswireHalozyme to Participate in Upcoming Investor Conferences
ZacksHalozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
ZacksHalozyme Therapeutics (HALO) Q1 Earnings Beat Estimates
PR NewswireHALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
BenzingaExpert Ratings For Halozyme Therapeutics
ZacksHalozyme Therapeutics (HALO) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
ZacksHalozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
PR NewswireMahesh Krishnan Elected to Halozyme's Board of Directors
ZacksWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
PR NewswireHalozyme to Report First Quarter 2024 Financial and Operating Results
ZacksHalozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
ZacksHalozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
Benzinga9 Analysts Have This To Say About Halozyme Therapeutics
ZacksHalozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
ZacksWhy Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
PR NewswireHalozyme to Participate in Upcoming Investor Conferences
PR NewswireHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
PR NewswireHalozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PR NewswireHalozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
PR NewswireHalozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PR NewswireHalozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
Wer­bung

Halozyme Therapeutics News

Halozyme Therapeutics News: auf dieser Seite finden Sie alle Halozyme Therapeutics News und Nachrichten zur Halozyme Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Halozyme Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Halozyme Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.